์ฝ˜ํ…์ธ ๋กœ ๊ฑด๋„ˆ๋›ฐ๊ธฐ
Merck

371725

GPR43 Agonist

>98% (HPLC), solid

๋™์˜์–ด(๋“ค):

GPR43 (FFA2) Agonist, (S)-2-(4-chlorophenyl)-3,3-dimethyl-N-(5-phenylthiazol-2-yl)butanamide

์กฐ์ง ๋ฐ ๊ณ„์•ฝ ๊ฐ€๊ฒฉ์„ ๋ณด๋ ค๋ฉด ๋กœ๊ทธ์ธ๋ฅผ ํด๋ฆญํ•ฉ๋‹ˆ๋‹ค.

ํฌ๊ธฐ ์„ ํƒ


์ œํ’ˆ์ •๋ณด (DICE ๋ฐฐ์†ก ์‹œ ๋น„์šฉ ๋ณ„๋„)

์‹คํ—˜์‹(Hill ํ‘œ๊ธฐ๋ฒ•):
C21H21ClN2OS
CAS ๋ฒˆํ˜ธ:
Molecular Weight:
384.92
MDL number:
UNSPSC Code:
51111800
NACRES:
NA.77
๊ธฐ์ˆ  ์„œ๋น„์Šค
๋„์›€์ด ํ•„์š”ํ•˜์‹ ๊ฐ€์š”? ์ €ํฌ ์ˆ™๋ จ๋œ ๊ณผํ•™์ž ํŒ€์ด ๋„์™€๋“œ๋ฆฌ๊ฒ ์Šต๋‹ˆ๋‹ค.
๋„์›€ ๋ฌธ์˜
๊ธฐ์ˆ  ์„œ๋น„์Šค
๋„์›€์ด ํ•„์š”ํ•˜์‹ ๊ฐ€์š”? ์ €ํฌ ์ˆ™๋ จ๋œ ๊ณผํ•™์ž ํŒ€์ด ๋„์™€๋“œ๋ฆฌ๊ฒ ์Šต๋‹ˆ๋‹ค.
๋„์›€ ๋ฌธ์˜

์ œํ’ˆ ์ด๋ฆ„

GPR43 (FFA2) Agonist, The GPR43 (FFA2) Agonist controls the biological activity of GPR43. This small molecule/inhibitor is primarily used for Biochemicals applications.

assay

>98% (HPLC)

form

solid

manufacturer/tradename

Calbiochemยฎ

storage condition

OK to freeze

color

white

solubility

DMSO: 50 mg/mL

shipped in

ambient

Quality Level

๊ด€๋ จ ์นดํ…Œ๊ณ ๋ฆฌ

General description

A phenylacetamide compound that acts as an allosteric agonist of FFA2 (GPR43), demonstrating a left-shifted acetate dose response (IC50 = 0.7 ยตM) and 111% efficacy relative to acetate in hFFA2 forskolin-induced cAMP assays.

Preparation Note

Following reconstitution, aliquot and freeze (-20ยฐC). Stock solutions are stable for up to 3 months at -20ยฐC.

Other Notes

Wang, Y., et al. 2009. Bioorg. Med. Chem. Lett.20, 493.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

์ €์žฅ ๋“ฑ๊ธ‰

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


์‹œํ—˜ ์„ฑ์ ์„œ(COA)

์ œํ’ˆ์˜ ๋กœํŠธ/๋ฐฐ์น˜ ๋ฒˆํ˜ธ๋ฅผ ์ž…๋ ฅํ•˜์—ฌ ์‹œํ—˜ ์„ฑ์ ์„œ(COA)์„ ๊ฒ€์ƒ‰ํ•˜์‹ญ์‹œ์˜ค. ๋กœํŠธ ๋ฐ ๋ฐฐ์น˜ ๋ฒˆํ˜ธ๋Š” ์ œํ’ˆ ๋ผ๋ฒจ์— ์žˆ๋Š” โ€˜๋กœํŠธโ€™ ๋˜๋Š” โ€˜๋ฐฐ์น˜โ€™๋ผ๋Š” ์šฉ์–ด ๋’ค์—์„œ ์ฐพ์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

์ด ์ œํ’ˆ์„ ์ด๋ฏธ ๊ฐ€์ง€๊ณ  ๊ณ„์‹ญ๋‹ˆ๊นŒ?

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ์—์„œ ์ตœ๊ทผ์— ๊ตฌ๋งคํ•œ ์ œํ’ˆ์— ๋Œ€ํ•œ ๋ฌธ์„œ๋ฅผ ์ฐพ์•„๋ณด์„ธ์š”.

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ ๋ฐฉ๋ฌธ

Sandra M Holmberg et al.
Nature communications, 15(1), 3502-3502 (2024-04-26)
Beneficial gut bacteria are indispensable for developing colonic mucus and fully establishing its protective function against intestinal microorganisms. Low-fiber diet consumption alters the gut bacterial configuration and disturbs this microbe-mucus interaction, but the specific bacteria and microbial metabolites responsible for
Anne ร˜rgaard et al.
Islets, 11(5), 103-111 (2019-08-31)
The intestinal microbiota has been demonstrated to influence host metabolism, and has been proposed to affect the development of obesity and type 2 diabetes (T2D), possibly through short-chain fatty acids (SCFAs) produced by fermentation of dietary fiber. There are some
Signe Schultz Pedersen et al.
The FEBS journal, 291(3), 566-583 (2023-11-21)
Butyrate, a gut microbial metabolite, has beneficial effects on glucose homeostasis and has become an attractive drug candidate for type 2 diabetes (T2D). Recently, we showed that butyrate protects pancreatic beta cells against cytokine-induced dysfunction. In this study, we explored
Guangwen Wang et al.
Journal of virology, 94(2) (2019-11-07)
Influenza A virus (IAV) coopts numerous host factors to complete its replication cycle. Here, we identify free fatty acid receptor 2 (FFAR2) as a cofactor for IAV entry into host cells. We found that downregulation of FFAR2 or Ffar2 expression
Josรฉ Luรญs Fachi et al.
The Journal of experimental medicine, 217(3) (2019-12-27)
Antibiotic-induced dysbiosis is a key predisposing factor for Clostridium difficile infections (CDIs), which cause intestinal disease ranging from mild diarrhea to pseudomembranous colitis. Here, we examined the impact of a microbiota-derived metabolite, short-chain fatty acid acetate, on an acute mouse

๊ตญ์ œ ๋ฌด์—ญ ํ’ˆ๋ชฉ ๋ฒˆํ˜ธ

SKUGTIN
371725-10MGCN04055977213270

์ž์‚ฌ์˜ ๊ณผํ•™์žํŒ€์€ ์ƒ๋ช… ๊ณผํ•™, ์žฌ๋ฃŒ ๊ณผํ•™, ํ™”ํ•™ ํ•ฉ์„ฑ, ํฌ๋กœ๋งˆํ† ๊ทธ๋ž˜ํ”ผ, ๋ถ„์„ ๋ฐ ๊ธฐํƒ€ ๋งŽ์€ ์˜์—ญ์„ ํฌํ•จํ•œ ๋ชจ๋“  ๊ณผํ•™ ๋ถ„์•ผ์— ๊ฒฝํ—˜์ด ์žˆ์Šต๋‹ˆ๋‹ค..

๊ณ ๊ฐ์ง€์›ํŒ€์œผ๋กœ ์—ฐ๋ฝ๋ฐ”๋ž๋‹ˆ๋‹ค.